FDA Approves Roche's Enspryng for Adults with Thyroid Eye Disease
Start here
The FDA has approved Roche's Enspryng (satralizumab), an IL-6 receptor antibody, to treat adults with thyroid eye disease (TED), Roche announced on October 16. It is described as the first and only at-home subcutaneous injection treatment for these patients. The drug was first approved by the FDA in August 2020 for neuromyelitis optica spectrum disorder (NMOSD) in adults, and TED is its second approved indication.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickFDA Approves Roche's Enspryng for Adults with Thyroid Eye Disease
The FDA has approved Roche's Enspryng (satralizumab), an IL-6 receptor antibody, to treat adults with thyroid eye disease (TED), Roche announced on October 16. It is described as the first and only at-home subcutaneous injection treatment for these patients. The drug was first approved by the FDA in August 2020 for neuromyelitis optica spectrum disorder (NMOSD) in adults, and TED is its second approved indication.
Heat trend for this story
Heat now 9·Peak in the comparable set 9 (Oct 16 17:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.